Total Reports
218
FDA CVM filings
Dog /
FDA CVM · 2025 release 218 reports on file
Griffon - French Wire-haired Pointing - FDA Adverse Event Profile
Adverse-event records for Griffon - French Wire-haired Pointing (Dog) from the FDA Center for Veterinary Medicine.
Data updated June 2026
The record at a glance
Griffon - French Wire-haired Pointing ranks #180 by report volume among dog breeds - 1 of 218 reports (0.5%) recorded a death outcome.
- #180
- most-reported dog breed
- 0.5%
- death-coded report share
- 39
- Vomiting - top reaction
- 4.4 yr
- average age at report
Read report counts next to breed popularity: a bigger number often just means more owners and more vet visits.
Deaths Reported
1
of 218 reports
Death Rate
0.5%
death-coded share
Avg Age at Report
4.4 yr
26.1 kg avg weight
Death-Coded Outcome Share
Griffon - French Wire-haired Pointing death-coded reports 0.5%
Cross-breed median
0.5% of 218 griffon - french wire-haired pointing reports involved a death outcome.
How to read this number
Read alongside breed popularity, veterinary access, and owner awareness, these shape how many events ever reach the FDA. The comparison line marks the cross-breed median death-coded share (about 4.8%) among breeds with 50 or more reports; values above it suggest higher reporting bias toward severe outcomes, not necessarily higher true mortality.
Average weight at time of report: 26.1 kg (57.6 lbs)
Top Reported Reactions
Vomiting 39
Lack of efficacy (endoparasite) - hookworm 24
Diarrhoea 21
Digestive tract disorder NOS 20
Lethargy (see also Central nervous system depression in 'Neurological') 19
Lack of efficacy (endoparasite) - heartworm 12
INEFFECTIVE, ASCARIDS NOS 11
Lack of efficacy (ectoparasite) - tick NOS 11
Most Referenced Drugs
Ivermectin + Pyrantel As Pamoate Salt 40
Afoxolaner 23
Milbemycin Oxime + Spinosad 20
Pyrantel Pamoate;Sarolaner 20
Fluralaner Chew Tablets 16
Milbemycin Oxime + Praziquantel 13
Bedinvetmab 11
Fluralaner 13.64% 12-Week Chew 9
Outcome Breakdown
Outcome Unknown
78 (37.7%)
Ongoing
68 (32.9%)
Recovered/Normal
54 (26.1%)
Recovered with Sequela
6 (2.9%)
Died
1 (0.5%)
Gender Distribution
Male 111 (50.9%)
Female 105 (48.2%)
Mixed 1 (0.5%)
Unknown 1 (0.5%)
Reports by Year
| Year | Reports | Trend |
|---|---|---|
| 2010 | 4 | |
| 2011 | 9 | |
| 2012 | 8 | |
| 2013 | 9 | |
| 2014 | 7 | |
| 2015 | 13 | |
| 2016 | 11 | |
| 2017 | 23 | |
| 2018 | 15 | |
| 2019 | 13 | |
| 2020 | 9 | |
| 2021 | 12 | |
| 2022 | 13 | |
| 2023 | 34 | |
| 2024 | 22 | |
| 2025 | 16 | |
Griffon - French Wire-haired Pointing Pet Health Insights
Griffon - French Wire-haired Pointing accounts for 218 FDA adverse event reports, ranking #180 by volume among dog breeds, with 1 reports (0.5%) coded as a death outcome. Mean age at report: 4.4 years, average weight 26.1 kg (57.6 lbs).
Top reported signs: Vomiting (39), Lack of efficacy (endoparasite) - hookworm (24), Diarrhoea (21). Most-referenced drug: Ivermectin + Pyrantel As Pamoate Salt (40 reports), followed by Afoxolaner (23) and Milbemycin Oxime + Spinosad (20).
Outcome coding on 207 status-recorded reports is dominated by Outcome Unknown (37.7%). Annual submissions ranged 2,010-2,025 across 16 years on file.
Dog Breeds With a Similar Report Volume
Frequently Asked Questions
How many FDA adverse event reports involve Griffon - French Wire-haired Pointing? ▼
There are 218 adverse event reports involving Griffon - French Wire-haired Pointing in the FDA database, with 1 reports involving death (0.5% death rate). Griffon - French Wire-haired Pointing ranks #180 by report volume.
What are the most common adverse reactions reported for Griffon - French Wire-haired Pointing? ▼
The most commonly reported adverse reactions for Griffon - French Wire-haired Pointing are Vomiting (39 reports), Lack of efficacy (endoparasite) - hookworm (24 reports), Diarrhoea (21 reports), Digestive tract disorder NOS (20 reports), Lethargy (see also Central nervous system depression in 'Neurological') (19 reports).
What drugs are most frequently associated with Griffon - French Wire-haired Pointing adverse events? ▼
The drugs most frequently referenced in Griffon - French Wire-haired Pointing adverse event reports are Ivermectin + Pyrantel As Pamoate Salt (40 reports), Afoxolaner (23 reports), Milbemycin Oxime + Spinosad (20 reports), Pyrantel Pamoate;Sarolaner (20 reports), Fluralaner Chew Tablets (16 reports).
What is the average age of Griffon - French Wire-haired Pointing in adverse event reports? ▼
The average age of Griffon - French Wire-haired Pointing at the time of adverse event reports is 4.4 years, with an average weight of 26.1 kg (57.6 lbs).
Does a high number of adverse event reports mean Griffon - French Wire-haired Pointing is unhealthy? ▼
No. FDA adverse event reports are voluntarily submitted and do not prove causation. Popular breeds with more veterinary visits tend to have more reports. The data reflects reporting patterns, not actual incidence rates. Always consult a veterinarian for health decisions.
Where does this Griffon - French Wire-haired Pointing safety data come from? ▼
All data comes from the FDA Center for Veterinary Medicine's adverse event reporting system. Pet owners, veterinarians, and manufacturers voluntarily submit reports about adverse events potentially linked to animal drugs and other products.
Compare a breed's report volume against how common the breed is before drawing conclusions. See our methodology for how death rate and rankings are computed.
Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. Breed figures are computed directly from FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.